Cargando…

Triggering drug use in patients with psoriasis: an investigative report from Turkey

INTRODUCTION: The patients clinically diagnosed with psoriasis were investigated for drug use that may trigger psoriasis. AIM: To minimize the triggering drug use and help the medical treatment of psoriasis patients. MATERIAL AND METHODS: The study involved 289 psoriatic patients who attended our cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogretmen, Zerrin, Askin, Ulku, Hiz, Meliha Merve, Cevizci, Sibel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221355/
https://www.ncbi.nlm.nih.gov/pubmed/25395925
http://dx.doi.org/10.5114/pdia.2014.44019
_version_ 1782342872927830016
author Ogretmen, Zerrin
Askin, Ulku
Hiz, Meliha Merve
Cevizci, Sibel
author_facet Ogretmen, Zerrin
Askin, Ulku
Hiz, Meliha Merve
Cevizci, Sibel
author_sort Ogretmen, Zerrin
collection PubMed
description INTRODUCTION: The patients clinically diagnosed with psoriasis were investigated for drug use that may trigger psoriasis. AIM: To minimize the triggering drug use and help the medical treatment of psoriasis patients. MATERIAL AND METHODS: The study involved 289 psoriatic patients who attended our clinic in 2010–2012 and were asked to bring their drug lists of the last year, which they obtained from the pharmacy's record system. They were advised not to use the drugs that may trigger psoriasis. Data analyses were performed using SPSS program version 19.0. RESULTS: A total of 289 patients were included in the study. Two hundred and twenty-one patients were using non-steroidal anti-inflammatory drugs; 133 patients were using anti-reflux drugs; 35 patients were using antidiabetic drugs; 31 patients were using calcium-channel blockers and 24 patients were using β-blockers. In our study group, there was no significantly difference between median PASI scores of the patients using a triggering drug and those of who are not using a triggering drug. However, there was a positive low correlation between PASI rates and numbers of drugs used (r = 0.180, p = 0.013). CONCLUSIONS: Many other factors may trigger psoriasis, therefore the effect of stopping or minimizing the drug use on disease remission is not known. Because of the high triggering drug use rate, it is important to enlighten psoriasis patients about triggering drugs.
format Online
Article
Text
id pubmed-4221355
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-42213552014-11-13 Triggering drug use in patients with psoriasis: an investigative report from Turkey Ogretmen, Zerrin Askin, Ulku Hiz, Meliha Merve Cevizci, Sibel Postepy Dermatol Alergol Original Paper INTRODUCTION: The patients clinically diagnosed with psoriasis were investigated for drug use that may trigger psoriasis. AIM: To minimize the triggering drug use and help the medical treatment of psoriasis patients. MATERIAL AND METHODS: The study involved 289 psoriatic patients who attended our clinic in 2010–2012 and were asked to bring their drug lists of the last year, which they obtained from the pharmacy's record system. They were advised not to use the drugs that may trigger psoriasis. Data analyses were performed using SPSS program version 19.0. RESULTS: A total of 289 patients were included in the study. Two hundred and twenty-one patients were using non-steroidal anti-inflammatory drugs; 133 patients were using anti-reflux drugs; 35 patients were using antidiabetic drugs; 31 patients were using calcium-channel blockers and 24 patients were using β-blockers. In our study group, there was no significantly difference between median PASI scores of the patients using a triggering drug and those of who are not using a triggering drug. However, there was a positive low correlation between PASI rates and numbers of drugs used (r = 0.180, p = 0.013). CONCLUSIONS: Many other factors may trigger psoriasis, therefore the effect of stopping or minimizing the drug use on disease remission is not known. Because of the high triggering drug use rate, it is important to enlighten psoriasis patients about triggering drugs. Termedia Publishing House 2014-10-22 2014-10 /pmc/articles/PMC4221355/ /pubmed/25395925 http://dx.doi.org/10.5114/pdia.2014.44019 Text en Copyright © 2014 Termedia http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Paper
Ogretmen, Zerrin
Askin, Ulku
Hiz, Meliha Merve
Cevizci, Sibel
Triggering drug use in patients with psoriasis: an investigative report from Turkey
title Triggering drug use in patients with psoriasis: an investigative report from Turkey
title_full Triggering drug use in patients with psoriasis: an investigative report from Turkey
title_fullStr Triggering drug use in patients with psoriasis: an investigative report from Turkey
title_full_unstemmed Triggering drug use in patients with psoriasis: an investigative report from Turkey
title_short Triggering drug use in patients with psoriasis: an investigative report from Turkey
title_sort triggering drug use in patients with psoriasis: an investigative report from turkey
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221355/
https://www.ncbi.nlm.nih.gov/pubmed/25395925
http://dx.doi.org/10.5114/pdia.2014.44019
work_keys_str_mv AT ogretmenzerrin triggeringdruguseinpatientswithpsoriasisaninvestigativereportfromturkey
AT askinulku triggeringdruguseinpatientswithpsoriasisaninvestigativereportfromturkey
AT hizmelihamerve triggeringdruguseinpatientswithpsoriasisaninvestigativereportfromturkey
AT cevizcisibel triggeringdruguseinpatientswithpsoriasisaninvestigativereportfromturkey